Hello criminal probe, goodbye hard-earned reputation — and, er, about seven per cent off Goldman Sachs’ stock, as at pixel time.
This note from a Merrill Lynch analyst says it all:
We are lowering our rating on GS to Neutral from Buy and our price objective to $160 from $220. Our downgrade is prompted by news reports filed Thursday evening by the media including the Wall St. Journal indicating that federal prosecutors have opened an investigation of GS in connection with its trading activities, raising the possibility of criminal charges.
As Guy Moszkowski explained:
PO of $160 discounts an ROE of 12%, by valuing the shares on 1.2x BVPS of $133 by the end of 10E. Though the firm’s long term earnings power is likely much higher, we expect the market to value shares at a discount given recent SEC charges and other negative headlines. Risks to PO: Earnings volatility, with GS registering ROE from negative in trough conditions to well over 20% in a peak market environment. Revenues can be lumpy. GS derives a high % of revenue from trading and market-making activities. GS’s business is balance-sheet intensive and has used high leverage which may be harder to carry as Bank Holding Co. While one source of GS’s ROE advantage is that it is good at spotting value, pricing illiquid assets, and taking risk, this means GS holds sizeable balances of illiquid securities subject to negative valuation adjustments. Going forward, inv’t banks and their leverage ratios will likely face greater gov’t scrutiny that could hinder returns. Given GS’s significant principal exposure, retracement of equity and debt market gains could result in losses.
GS is also exposed to headline and litigation risk. The firm has been under increased media and political scrutiny over the last few months.
Oh, S&P Equity Research cut Goldman to sell from hold.
The target price? $140 from $180.
The price of Goldman settling with the SEC over its civil fraud case in the first place? Probably worth it.
Article Series - Abacus
- SEC charges Goldman Sachs with subprime fraud
- The case involving ABACUS 2007-AC1
- Markets Live transcript - Goldman/SEC special - 16 Apr 2010
- Formerly The Greatest Trade Ever
- Paulson: 'It's our money now'
- SEC/Goldman linkfest
- Introducing Fabrice "fabulous Fab" Tourre
- 'Goldman Sachs is disappointed...'
- This CDO is a Democrat
- ACA's rather disastrous CDO forays
- The analysts react
- A Goldman blogger round-up
- A CDO litigation risk league table
- Fisking Goldman's latest rebuttal
- The Goldman defence documents
- Fabrice Tourre scores an indefinite paid holiday
- Der Abakus
- Is this the sound of a bandwagon?
- The experience of Laura Schwartz
- Fabrice Tourre goes underground
- The exemplary Magnetar CDOs
- Dear Paulson investor...
- Appearing soon in the Senate - fabulous Fab (updated)
- In defence of Goldman Sachs
- For RBS, a routine deal became an $840m mistake
- The prospectus
- More Goldman voyeurism
- Tail risk in the Rhineland
- The running order in Room 106
- 'My name is Fabrice Tourre'
- Live, from Room 106
- Goldman in DC: A blogger round-up
- Call the cops
- Understated Research Headline of the Year, Part II
- Goldman TV
- Fitch revises Goldman to outlook negative
- The many legal risks of Goldman
- Goldman faces new CDO case
- Goldman's shares hit 52-week low

